PCM
IMDX

Perkins Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Perkins Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,986
Closed -$55K – 107
2020
Q3 		$55K Buy
+1,986
New +$56.9K 0.05% 87
2020
Q1 		$53K Buy
+1,086
New +$53.2K 0.06% 91
2019
Q2 		– Sell
-1,250
Closed -$99K – 120
2019
Q1 		$99K Buy
+1,250
New +$80.6K 0.07% 118

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Perkins Capital Management's IMDX Position: Q4 2020 in Review

Perkins Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 1,986 shares — an estimated $55K sold.

Perkins Capital Management first reported a position in IMDX in Q1 2019 and held it in 3 quarters. The position peaked at $99K in Q1 2019. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • Perkins Capital Management reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • Perkins Capital Management sold 1,986 Insight Molecular Diagnostics shares in Q4 2020, an estimated $55K.
  • Perkins Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 3 quarters.
  • Perkins Capital Management's Insight Molecular Diagnostics position peaked at $99K in Q1 2019.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on Perkins Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.